 Home > Encyclopedia > Terazosin hydrochloride

Terazosin hydrochloride

Terazosin hydrochloride structure

CAS No:
63074-08-8
Formula:
C19H25N5O4.ClH
Chemical Name:
Terazosin hydrochloride
Synonyms:
Methanone,[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-,hydrochloride (1:1);Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-,monohydrochloride;2-[4-(Tetrahydro-2-furoyl)-piperazine]-4-amino-6,7-dimethoxyquinazoline-hydrochloride;Terazosin hydrochloride;Hytrin;Vasocard;Abbott 45975;1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride;Terasin;Hytracin;Olyster;Dysalfa;Tructum;Heitrin;Vicard;Hytrine;Hytrinex;Itrin;Teralfa;Vasomet;Flotrin;Hitrin;Rotiaz;Flumarc;Terazin
Categories:
Active Pharmaceutical Ingredients > Circulatory System Drugs

Request for Quotation

Terazosin hydrochloride Basic Attributes

Molecular Weight：

423.89

Exact Mass：

423.167

EC Number：

613-138-7

NSC Number：

759168

DSSTox ID：

DTXSID7045493

Characteristics

PSA：

103

XLogP3：

1.64090

Appearance：

white to off-white powder

Density：

1.3±0.1 g/cm3

Boiling Point：

664.5ºC at 760 mmHg

Flash Point：

355.7±34.3 °C

Refractive Index：

1.636

Water Solubility：

soluble in water at 20mg/ml. Also soluble in methanol or ethanol.

Storage Conditions：

Store at RT

Vapor Pressure：

1.59E-17mmHg at 25°C

Collision Cross Section：

195.7 Å² [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Safety Information

wgk germany：

hazard class code：

22-36/37/38

safety instructions：

26-36

RTECS Number：

TK8044925

Marks：

Xn,Xi

Precautionary statement(s)：

P201, P202, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P330, P337+P313, P405, P501

Hazard Statements：

H302

GHS Classification：

|Warning|H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P330, P337+P313, P405, and P501|Aggregated GHS information provided by 3 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

MeSH：

Drugs used in the treatment of urogenital conditions and diseases such as URINARY INCONTINENCE; PROSTATIC HYPERPLASIA; and ERECTILE DYSFUNCTION. (See all compounds classified as Urological Agents.)|Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)

MeSH Entry Terms：

A 45975

Terazosin hydrochloride Use and Manufacturing

Uses

Hytrin (Abbott).

Use Classification：

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:423.9
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:4
Exact Mass:423.1673320
Monoisotopic Mass:423.1673320
Topological Polar Surface Area:103
Heavy Atom Count:29
Complexity:544
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

This product is a selective alpha 1 receptor blocker that can reduce peripheral vascular resistance and has a lowering effect on both systolic and diastolic blood pressure; it has the effect of relaxing bladder and prostate smooth muscles and can relieve the symptoms of dysuria caused by benign prostatic hypertrophy.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Terazosin Hydrochloride Tablets
Ingredients	The main ingredient of this product is: terazosin hydrochloride.
Indication	In clinical trials, the proportion of patients who reported dizziness or other related adverse reactions in patients treated with this product and angiotensin (ACE) inhibitors or diuretics was higher than the proportion of all patients treated with this product. When this product is used in combination with other antihypertensive drugs, care should be taken to avoid significant hypotension. When this product is added to diuretics or other antihypertensive drugs, the dose should be reduced and re-formulated if necessary. It is known that this product does not interact with analgesics/anti-inflammatory drugs, cardiac glycosides, hypoglycemic drugs, antiarrhythmic drugs, antianxiety drugs/sedatives, antibacterial drugs, hormones/steroids and gout treatment drugs.
Specifications	5 mg (calculated as C19H25N504HCl)
Manufacturer	Suzhou Dawnrays Pharmaceutical Co., Ltd.

Terazosin Hydrochloride Tablets
Ingredients	Terazosin hydrochloride.
Indication	1. In clinical trials, the proportion of patients who reported dizziness or other related adverse reactions in patients who were treated with this product in combination with angiotensin (ACE) inhibitors and diuretics was higher than the proportion of all patients treated with this product. When this product is used in combination with other antihypertensive drugs, care should be taken to avoid significant hypotension. When this product is added to diuretics or other antihypertensive drugs, the dose should be reduced and re-formulated if necessary. 2. It is known that this product will not interact with analgesics/anti-inflammatory drugs, cardiac glycosides, hypoglycemic drugs, antiarrhythmic drugs, antianxiety drugs/sedatives, antibacterial drugs, hormones/steroids and gout treatment drugs.
Specifications	2mg (calculated as C19H25N5O4)
Manufacturer	Shanghai Zhonghua Pharmaceutical Co., Ltd.

Terazosin Hydrochloride Tablets
Ingredients	The main ingredient of this product is: terazosin hydrochloride. Its chemical name is: 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydrofuran-2-formyl)piperazine, monohydrochloride dihydrate.
Indication	In clinical trials, the proportion of patients who reported dizziness or other related adverse reactions in patients treated with this product in combination with angiotensin (ACE) inhibitors and diuretics was higher than the proportion of all patients treated with this product. When this product is used in combination with other antihypertensive drugs, care should be taken to avoid significant hypotension. When this product is added to diuretics or other antihypertensive drugs, the dose should be reduced and re-formulated if necessary.
Specifications	2mg
Manufacturer	Henan Taloph Pharmaceutical Stock Co., Ltd.

See More Related Drugs

Registered Holders

BIOPHORE INDIA PHARMACEUTICALS PVT LTD

United States
Active
APITORIA PHARMA PRIVATE LTD

United States
Active
JUBILANT PHARMOVA LTD

United States
Active

See More Registered Holders

Recommended Suppliers of Terazosin hydrochloride

HANGZHOU LEAP CHEM CO., LTD. Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives

Terazosin hydrochloride

CAS No.: 63074-08-8

Content: 99.00%

Inquiry
Shaanxi TNJONE Pharmaceutical Co., Ltd Contact Supplier

CN
2 YRS

Business licensed Certified factory

Manufactory Supplier of Semaglutide,Tirzepatide,API,Vitamins,Food Additive

API 99% Purity CAS 63074-08-8 Terazosin HCl Powder Pharmaceutical Grade

CAS No.: 63074-08-8

Grade: Top Product

Content: 99%

Inquiry
Xian ZB Biotech Co.,Ltd Contact Supplier

CN
5 YRS

Business licensed Certified factory

Manufactory Supplier of Herb Extracts,Cosmetic raw materails,API

High Quality API Terazosin HCl CAS 63074-08-8

CAS No.: 63074-08-8

Grade: Pharmaceutical Grade

Content: 99%

Inquiry